OBJECTIVE: Impaired regulation of Aurora-B/AIM-1 expression in human cells causes chromosomal abnormality and instability, and recent observations of high expression but not mutation of Aurora-B/AIM-1 in human cancers imply that Aurora-B/AIM-1 might be a candidate molecule for cancer progression. We analyzed the effects of modification of Aurora-B/AIM-1 expression on the growth of a human glioma cell line and the expression of Aurora-B/AIM-1 in astrocytomas. METHODS: A glioma cell line, U251MG was transfected with wild type (WT) of Aurora-B/AIM-1 or kinase-inactive mutant of Aurora-B/AIM-1 in order to test the effects of overexpression of WT or kinase-inactive Aurora-B/AIM-1 on cell morphology and cell growth. Brain tissue samples were obtained during surgery and processed for reverse transcription-polymerase chain reaction, immunofluorescence in order to analyze the expression of Aurora-B/AIM-1 mRNA and protein. RESULTS: Exogenous overexpression of WT of Aurora-B/AIM-1 in cultured cells of U251MG produced multinuclearity and increased ploidy, and inhibited the growth of tumor cells. Exogenous overexpression of kinase-inactive Aurora-B/AIM-1 in a human glioma cell line also suppressed the tumor cell growth without affecting ploidy. Aurora-B/AIM-1 was highly expressed in astrocytomas and U251MG, and mRNA and protein levels of Aurora-B/AIM-1 in tumor tissues well correlated with their histological malignancy (World Health Organization grading). Survival time also negatively correlated with the levels of Aurora-B/AIM-1 mRNA in tumor samples. CONCLUSION: Aurora-B/AIM-1 was highly expressed in high-grade gliomas and its expression was well correlated with histological malignancy and clinical outcomes. The modification of the level of Aurora-B/AIM-1 expression might be a new target for glioma therapy.
OBJECTIVE: Impaired regulation of Aurora-B/AIM-1 expression in human cells causes chromosomal abnormality and instability, and recent observations of high expression but not mutation of Aurora-B/AIM-1 in humancancers imply that Aurora-B/AIM-1 might be a candidate molecule for cancer progression. We analyzed the effects of modification of Aurora-B/AIM-1 expression on the growth of a humanglioma cell line and the expression of Aurora-B/AIM-1 in astrocytomas. METHODS: A glioma cell line, U251MG was transfected with wild type (WT) of Aurora-B/AIM-1 or kinase-inactive mutant of Aurora-B/AIM-1 in order to test the effects of overexpression of WT or kinase-inactive Aurora-B/AIM-1 on cell morphology and cell growth. Brain tissue samples were obtained during surgery and processed for reverse transcription-polymerase chain reaction, immunofluorescence in order to analyze the expression of Aurora-B/AIM-1 mRNA and protein. RESULTS: Exogenous overexpression of WT of Aurora-B/AIM-1 in cultured cells of U251MG produced multinuclearity and increased ploidy, and inhibited the growth of tumor cells. Exogenous overexpression of kinase-inactive Aurora-B/AIM-1 in a humanglioma cell line also suppressed the tumor cell growth without affecting ploidy. Aurora-B/AIM-1 was highly expressed in astrocytomas and U251MG, and mRNA and protein levels of Aurora-B/AIM-1 in tumor tissues well correlated with their histological malignancy (World Health Organization grading). Survival time also negatively correlated with the levels of Aurora-B/AIM-1 mRNA in tumor samples. CONCLUSION:Aurora-B/AIM-1 was highly expressed in high-grade gliomas and its expression was well correlated with histological malignancy and clinical outcomes. The modification of the level of Aurora-B/AIM-1 expression might be a new target for glioma therapy.
Authors: Peter H Wessels; Albert Twijnstra; Alfons G H Kessels; Bela Krijne-Kubat; Paul H Theunissen; Monique I J Ummelen; Frans C S Ramaekers; Anton H Hopman Journal: Genes Chromosomes Cancer Date: 2002-03 Impact factor: 5.006
Authors: R R Adams; D M Eckley; P Vagnarelli; S P Wheatley; D L Gerloff; A M Mackay; P A Svingen; S H Kaufmann; W C Earnshaw Journal: Chromosoma Date: 2001-05 Impact factor: 4.316
Authors: Matthias C Schmidt; Sven Antweiler; Nina Urban; Wolf Mueller; A Kuklik; Birgit Meyer-Puttlitz; Otmar D Wiestler; David N Louis; Rolf Fimmers; Andreas von Deimling Journal: J Neuropathol Exp Neurol Date: 2002-04 Impact factor: 3.685
Authors: T Warr; S Ward; J Burrows; B Harding; P Wilkins; W Harkness; R Hayward; J Darling; D Thomas Journal: Genes Chromosomes Cancer Date: 2001-05 Impact factor: 5.006
Authors: H Köck; M P Harris; S C Anderson; T Machemer; W Hancock; S Sutjipto; K N Wills; R J Gregory; H M Shepard; M Westphal; D C Maneval Journal: Int J Cancer Date: 1996-09-17 Impact factor: 7.396
Authors: Kleiton Silva Borges; Angel Maurício Castro-Gamero; Daniel Antunes Moreno; Vanessa da Silva Silveira; Maria Sol Brassesco; Rosane Gomes de Paula Queiroz; Harley Francisco de Oliveira; Carlos Gilberto Carlotti; Carlos Alberto Scrideli; Luiz Gonzaga Tone Journal: J Cancer Res Clin Oncol Date: 2011-12-09 Impact factor: 4.553
Authors: Dimpy Koul; Jun Fu; Ruijun Shen; Tiffany A LaFortune; Shuzhen Wang; Ningyi Tiao; Yong-Wan Kim; Juinn-Lin Liu; Deepti Ramnarian; Ying Yuan; Carlos Garcia-Echevrria; Sauveur-Michel Maira; W K Alfred Yung Journal: Clin Cancer Res Date: 2011-11-07 Impact factor: 12.531
Authors: Kenneth J Niermann; Luigi Moretti; Nicholas J Giacalone; Yunguang Sun; Stephen M Schleicher; Prapaporn Kopsombut; Lauren R Mitchell; Kwang Woon Kim; Bo Lu Journal: Radiat Res Date: 2011-01-11 Impact factor: 2.841
Authors: Espen Burum-Auensen; Rolf I Skotheim; Aasa R Schjølberg; Jo Røislien; Ragnhild A Lothe; Ole Petter F Clausen Journal: J Carcinog Date: 2010-03-04
Authors: Cornelia Man; Jack Rosa; Y L Yip; Annie Lai-Man Cheung; Y L Kwong; Stephen J Doxsey; S W Tsao Journal: Mol Biol Cell Date: 2008-03-19 Impact factor: 4.138